First Financial Bankshares Inc Buys 13,399 Shares of Medtronic PLC $MDT

First Financial Bankshares Inc raised its stake in Medtronic PLC (NYSE:MDT) by 2.0% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 689,391 shares of the medical technology company’s stock after purchasing an additional 13,399 shares during the quarter. Medtronic makes up about 1.3% of First Financial Bankshares Inc’s portfolio, making the stock its 27th biggest holding. First Financial Bankshares Inc owned 0.05% of Medtronic worth $65,658,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Norges Bank bought a new position in shares of Medtronic in the second quarter valued at $1,432,698,000. Guinness Asset Management LTD acquired a new stake in Medtronic in the third quarter valued at $275,556,000. Vanguard Group Inc. grew its position in shares of Medtronic by 1.5% in the 2nd quarter. Vanguard Group Inc. now owns 126,909,406 shares of the medical technology company’s stock valued at $11,062,693,000 after acquiring an additional 1,895,165 shares during the period. Bessemer Group Inc. grew its position in shares of Medtronic by 86.2% in the 3rd quarter. Bessemer Group Inc. now owns 2,538,029 shares of the medical technology company’s stock valued at $241,723,000 after acquiring an additional 1,174,765 shares during the period. Finally, Arrowstreet Capital Limited Partnership increased its stake in shares of Medtronic by 332.0% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 1,494,782 shares of the medical technology company’s stock worth $130,300,000 after purchasing an additional 1,148,803 shares during the last quarter. Institutional investors own 82.06% of the company’s stock.

Key Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Received CE mark for its next‑gen GI Genius module and ColonPRO software — expands regulatory clearance and commercial runway in GI imaging, a clear revenue catalyst. Medtronic wins CE mark for next-gen GI Genius module, ColonPRO software
• Positive Sentiment: Recognized at the 2026 Dorian Awards for structured problem‑solving excellence — a reputational boost that supports brand value with hospitals and enterprise customers. 2026 DORIAN AWARDS RECOGNIZE GLOBAL LEADERS IN STRUCTURED PROBLEM-SOLVING EXCELLENCE
• Positive Sentiment: Multiple investor pieces highlight Medtronic’s strong dividend profile and defensive cash flows, reinforcing interest from income-seeking investors and supporting the share price floor. 1 Reason I’d Buy Medtronic Stock and Never Sell
• Neutral Sentiment: BTIG maintained a Hold rating on MDT — not bearish but keeps analyst sentiment from turning strongly positive. BTIG Sticks to Its Hold Rating for Medtronic (MDT)
• Neutral Sentiment: Valuation/returns analysis pieces point to mixed long‑term returns and prompt investors to reassess fair value — supports trading volatility but not a clear directional signal. Is It Time To Reconsider Medtronic (MDT) After Mixed Long Term Share Returns
• Neutral Sentiment: Industry podcast and revenue roundups highlight broader medtech winners from 2025 — useful context for sector positioning but not company‑specific catalysts. Podcast: Which pharma and medtech companies came out on top in 2025 revenues?
• Neutral Sentiment: Coverage of broader trade/tariff uncertainty underscores a macro risk — CEOs want policy clarity, which could affect multinational supply chains and sentiment for global medtech firms like Medtronic. Veteran CEO: President Trump’s chaotic tariff policy is not working

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. Piper Sandler reiterated a “neutral” rating on shares of Medtronic in a report on Monday, January 5th. Needham & Company LLC reduced their target price on Medtronic from $121.00 to $120.00 and set a “buy” rating for the company in a research note on Tuesday, February 17th. Truist Financial decreased their target price on Medtronic from $107.00 to $103.00 and set a “hold” rating on the stock in a report on Wednesday, February 18th. Royal Bank Of Canada raised their price target on Medtronic from $111.00 to $118.00 and gave the company an “outperform” rating in a report on Wednesday, November 19th. Finally, Wells Fargo & Company started coverage on shares of Medtronic in a research report on Friday, January 30th. They set an “overweight” rating and a $114.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and ten have issued a Hold rating to the company. According to MarketBeat.com, Medtronic presently has a consensus rating of “Moderate Buy” and a consensus target price of $110.84.

Medtronic Price Performance

Shares of NYSE MDT opened at $98.54 on Tuesday. The business has a fifty day moving average price of $99.03 and a two-hundred day moving average price of $96.80. The stock has a market capitalization of $126.33 billion, a PE ratio of 27.45, a P/E/G ratio of 2.43 and a beta of 0.71. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.42 and a quick ratio of 1.80. Medtronic PLC has a fifty-two week low of $79.55 and a fifty-two week high of $106.33.

Medtronic (NYSE:MDT) last issued its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, topping analysts’ consensus estimates of $1.34 by $0.02. The company had revenue of $9.02 billion for the quarter, compared to analysts’ expectations of $8.89 billion. Medtronic had a return on equity of 14.88% and a net margin of 13.00%.Medtronic’s revenue was up 5.8% on a year-over-year basis. During the same quarter last year, the business earned $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, equities analysts predict that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, January 16th. Stockholders of record on Friday, December 26th were given a $0.71 dividend. The ex-dividend date was Friday, December 26th. This represents a $2.84 annualized dividend and a dividend yield of 2.9%. Medtronic’s payout ratio is presently 79.11%.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).